13F Holdings
中文EN

IBRX ImmunityBio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1326110 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY121.2%
TTM net income YoY-218.3%
TTM EPS YoY-158.5%
Revenue 3-yr CAGR589.9%
Net income 3-yr CAGR—

Margins

Gross margin98.8%
Operating margin-150.2%
Net margin-607.8%
FCF margin-162.5%
EBITDA margin-141.1%

Returns

ROE—
ROA-196.7%
ROIC (approx.)—
Asset turnover0.32x

Leverage & solvency

Liabilities / assets288.0%
Debt / equity—
Current ratio4.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.26x
Accruals ratio-145.7%
Payout ratio—
Capex / revenue5.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$113.29M$14.74M$622,000$240,000$934,000
Cost of revenue$753,000$0$0$0—
Gross profit$112.53M$14.74M$622,000$240,000—
R&D expense—$190.14M$232.37M$248.15M$195.96M
SG&A expense—$168.78M$129.62M$102.71M$135.26M
Operating income-$256.03M-$344.18M-$362.25M-$351.30M-$330.28M
Interest expense$60.89M$114.59M$128.85M$63.52M$14.85M
Pretax income-$351.61M-$413.64M-$583.89M-$417.29M-$349.84M
Income tax-$135,000$0-$40,000$34,000$9,000
Net income-$351.40M-$413.56M-$583.20M-$416.57M-$346.79M
EBITDA-$240.50M-$326.63M-$343.74M-$333.04M-$316.04M
EPS (basic)-0.38-0.59-1.15-1.04-0.89
EPS (diluted)-0.38-0.62-1.15-1.04-0.89
Weighted avg. shares (diluted)919.86M700.44M508.64M399.90M389.23M
Balance sheet
Cash & equivalents$88.33M$143.43M$265.45M$104.64M$181.10M
Short-term investments$154.48M$6.38M$1.01M$2.54M$136.01M
Receivables$42.57M$2.36M$0——
Inventory$910,000$8.27M$0——
Current assets$314.88M$184.59M$294.08M$140.58M$334.35M
PP&E, net$114.26M$137.09M$146.08M$143.66M$82.86M
Goodwill$910,000$910,000———
Intangibles$12.99M$14.53M$17.09M$20.00M$1.42M
Total assets$501.90M$382.93M$504.45M$362.36M$468.91M
Current liabilities$61.75M$54.94M$58.28M$500.86M$369.00M
Short-term debt$1.75M$1.25M———
Total liabilities$1.00B$871.06M$1.09B$812.18M$712.82M
Shareholders' equity-$500.47M-$489.10M-$586.99M-$447.33M-$242.17M
Shares outstanding1.01B852.90M670.87M421.57M397.83M
Cash flow statement
Operating cash flow-$304.94M-$391.24M-$366.76M-$337.51M-$274.42M
Capital expenditure$3.85M$6.89M$30.58M$78.16M$33.56M
Free cash flow-$308.78M-$398.12M-$397.34M-$415.67M-$307.98M
Investing cash flow-$149.80M-$12.25M-$30.47M$27.30M-$84.89M
Financing cash flow$400.24M$281.63M$558.34M$233.61M$505.44M
Depreciation & amortization$15.53M$17.55M$18.51M$18.26M$14.24M
Stock-based compensation$36.81M$34.43M$49.16M$40.18M$57.18M
Share buybacks————$0

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.